Literature DB >> 1379414

Development, multiplexing, and application of ARMS tests for common mutations in the CFTR gene.

R M Ferrie1, M J Schwarz, N H Robertson, S Vaudin, M Super, G Malone, S Little.   

Abstract

The amplification refractory mutation system (ARMS) is a simple, rapid and reliable method for the detection of any mutation involving single base changes or small deletions. We have applied ARMS methodology to the detection of mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. Single ARMS tests have been developed for 11 CFTR mutations found in the northwest of England. ARMS reactions for the most common mutations have been multiplexed to give a test which will detect the presence of the delta F508, G551D, G542X, and 621 + 1G----T mutations in a DNA sample. The multiplex test has been validated by the analysis of over 500 previously genotyped samples and has been found to be completely accurate. The rapid detection of the most common mutations has enabled early molecular confirmation of suspected cystic fibrosis in neonates, rapid typing of cystic fibrosis patients and their relatives, and testing of sperm and egg donors.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1379414      PMCID: PMC1682690     

Source DB:  PubMed          Journal:  Am J Hum Genet        ISSN: 0002-9297            Impact factor:   11.025


  33 in total

1.  Detection of specific sequences among DNA fragments separated by gel electrophoresis.

Authors:  E M Southern
Journal:  J Mol Biol       Date:  1975-11-05       Impact factor: 5.469

Review 2.  The polymerase chain reaction in an anemic mode: how to avoid cold oligodeoxyribonuclear fusion.

Authors:  K B Mullis
Journal:  PCR Methods Appl       Date:  1991-08

3.  Direct gene diagnosis of cystic fibrosis by allele-specific polymerase chain reactions.

Authors:  M Wagner; M Schloesser; J Reiss
Journal:  Mol Biol Med       Date:  1990-08

4.  Rapid detection and prenatal diagnosis of beta-thalassaemia: studies in Indian and Cypriot populations in the UK.

Authors:  J M Old; N Y Varawalla; D J Weatherall
Journal:  Lancet       Date:  1990-10-06       Impact factor: 79.321

5.  Minisatellite repeat coding as a digital approach to DNA typing.

Authors:  A J Jeffreys; A MacLeod; K Tamaki; D L Neil; D G Monckton
Journal:  Nature       Date:  1991-11-21       Impact factor: 49.962

6.  Analysis of enzymatically amplified beta-globin and HLA-DQ alpha DNA with allele-specific oligonucleotide probes.

Authors:  R K Saiki; T L Bugawan; G T Horn; K B Mullis; H A Erlich
Journal:  Nature       Date:  1986 Nov 13-19       Impact factor: 49.962

7.  A highly polymorphic locus in human DNA.

Authors:  A R Wyman; R White
Journal:  Proc Natl Acad Sci U S A       Date:  1980-11       Impact factor: 11.205

8.  A cluster of cystic fibrosis mutations in the first nucleotide-binding fold of the cystic fibrosis conductance regulator protein.

Authors:  G R Cutting; L M Kasch; B J Rosenstein; J Zielenski; L C Tsui; S E Antonarakis; H H Kazazian
Journal:  Nature       Date:  1990-07-26       Impact factor: 49.962

9.  Identification of mutations in exons 1 through 8 of the cystic fibrosis transmembrane conductance regulator (CFTR) gene.

Authors:  J Zielenski; D Bozon; B Kerem; D Markiewicz; P Durie; J M Rommens; L C Tsui
Journal:  Genomics       Date:  1991-05       Impact factor: 5.736

10.  Benign missense variations in the cystic fibrosis gene.

Authors:  K Kobayashi; M R Knowles; R C Boucher; W E O'Brien; A L Beaudet
Journal:  Am J Hum Genet       Date:  1990-10       Impact factor: 11.025

View more
  47 in total

1.  Failure to refer for testing for cystic fibrosis. Doctors must ensure that those with a family history are advised appropriately.

Authors:  M Super; R Barnes; D Greig
Journal:  BMJ       Date:  2001-02-10

2.  Cystic fibrosis genotypes and views on screening are both heterogeneous and population related.

Authors:  C R Scriver; T M Fujiwara
Journal:  Am J Hum Genet       Date:  1992-11       Impact factor: 11.025

3.  Expanded newborn screening in Greece: 30 months of experience.

Authors:  Yannis L Loukas; Georgios-Stefanos Soumelas; Yannis Dotsikas; Vassiliki Georgiou; Elina Molou; Georgia Thodi; Maria Boutsini; Sofia Biti; Konstantinos Papadopoulos
Journal:  J Inherit Metab Dis       Date:  2010-08-19       Impact factor: 4.982

4.  Screening for the Most Common Mutations of CFTR Gene among Egyptian Children with Difficult-to-Treat Asthma.

Authors:  Mohammad Al-Haggar; Engy Osman; Abdel-Rahman Eid; Tarek Barakat; Samar El-Morsi
Journal:  J Pediatr Genet       Date:  2020-02-03

Review 5.  The genetic basis of disease.

Authors:  Maria Jackson; Leah Marks; Gerhard H W May; Joanna B Wilson
Journal:  Essays Biochem       Date:  2018-12-02       Impact factor: 8.000

6.  CFTR Gene Mutations and Asthma in Indian Children: A Case-Control Study.

Authors:  Pratibha Dixit; Shally Awasthi; Nutan Maurya; Sarita Agarwal; M Srinivasan
Journal:  Indian J Clin Biochem       Date:  2013-11-22

7.  The founder mutations 185delAG and 5382insC in BRCA1 and 6174delT in BRCA2 appear in 60% of ovarian cancer and 30% of early-onset breast cancer patients among Ashkenazi women.

Authors:  D Abeliovich; L Kaduri; I Lerer; N Weinberg; G Amir; M Sagi; J Zlotogora; N Heching; T Peretz
Journal:  Am J Hum Genet       Date:  1997-03       Impact factor: 11.025

8.  Use of chimeric DNA-RNA primers in quantitative PCR for detection of Ehrlichia canis and Babesia canis.

Authors:  Ofer Peleg; Gad Baneth; Osnat Eyal; Jacob Inbar; Shimon Harrus
Journal:  Appl Environ Microbiol       Date:  2009-07-24       Impact factor: 4.792

9.  Pulmonary outcome in cystic fibrosis is influenced primarily by mucoid Pseudomonas aeruginosa infection and immune status and only modestly by genotype.

Authors:  R B Parad; C J Gerard; D Zurakowski; D P Nichols; G B Pier
Journal:  Infect Immun       Date:  1999-09       Impact factor: 3.441

10.  Cystic fibrosis carrier testing in early pregnancy by general practitioners.

Authors:  H Harris; D Scotcher; N Hartley; A Wallace; D Craufurd; R Harris
Journal:  BMJ       Date:  1993-06-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.